NEW YORK--(BUSINESS WIRE)--Retrophin, Inc. (OTCQB:RTRX) today announced that it has agreed to support the completion of a Phase II clinical trial of oxytocin for the treatment of schizophrenia directed by Dr. David Feifel, Department of Psychiatry, University of California, San Diego. The study will become part of the company’s clinical development program for Syntocinon™.
Help employers find you! Check out all the jobs and post your resume.
